We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
- Authors
Jagannath, Sundar; Vij, Ravi; Stewart, A Keith; Trudel, Suzanne; Jakubowiak, Andrzej J; Reiman, Tony; Somlo, George; Bahlis, Nizar; Lonial, Sagar; Kunkel, Lori A; Wong, Alvin; Orlowski, Robert Z; Siegel, David S
- Abstract
An open-label single-arm multicenter pilot phase II study of the next-generation selective proteasome inhibitor carfilzomib was conducted in 46 patients with relapsed and refractory multiple myeloma (MM) after ≥ 2 previous therapies. The best overall response rate (ORR) was 16.7%, with a median duration of response of 7.2 months. This pilot study was the first phase II single-agent trial conducted with carfilzomib.
- Publication
Clinical lymphoma, myeloma & leukemia, 2012, Vol 12, Issue 5, p310
- ISSN
2152-2669
- Publication type
Journal Article
- DOI
10.1016/j.clml.2012.08.003